Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL937164 | 0.86 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3MAOBKDM1A | |
| SCHEMBL6481644 | 0.86 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3MAOBKDM1A | |
| SCHEMBL4724585 | 0.84 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3MAOBKDM1A | |
| SCHEMBL14205859 | 0.81 | MAOB (0.50) | SLC6A2SLC6A4SLC6A3MAOBKDM1A | |
| SCHEMBL27301212 | 0.80 | LMNA (0.48) | KDM1AHTR2CNPC1CYP19A1DRD2 | |
| SCHEMBL31367100 | 0.77 | KDM1A (0.46) | SLC6A2SLC6A4SLC6A3MAOBKDM1A | |
| SCHEMBL8200366 | 0.77 | MAOA (0.46) | SLC6A2SLC6A4SLC6A3MAOBKDM1A | |
| SCHEMBL11892830 | 0.76 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3MAOBKDM1A | |
| SCHEMBL13651792 | 0.75 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3MAOBKDM1A | |
| SCHEMBL5853845 | 0.75 | TSHR (0.41) | SLC6A2SLC6A4SLC6A3MAOBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016142952-A1 | PROCESS FOR PREPARATION OF VILAZODONE AND ITS NOVEL INTERMEDIATES | NOSCH LABS PRIVATE LIMITED (IN) | 2016-09-15 | — | — | WO | claimed |
| WO-2025050647-A1 | IONIZABLE CATIONIC LIPID COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 晟迪生物医药(苏州)有限公司 | 2025-03-13 | — | — | WO | disclosed |
| CN-117986153-A | Ionizable cationic lipid compound, and preparation method and application thereof | 晟迪生物医药(苏州)有限公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2016142952-A1 | PROCESS FOR PREPARATION OF VILAZODONE AND ITS NOVEL INTERMEDIATES | NOSCH LABS PRIVATE LIMITED (IN) | 2016-09-15 | — | — | WO | disclosed |
| US-9035070-B2 | Process for the preparation of 1-aryl-pyrazol-3-one intermediates useful in the synthesis of sigma receptors inhibitors | Esteve Química, S.A. (ES) | 2015-05-19 | — | — | US | disclosed |
| EP-2598469-B1 | PROCESS FOR THE PREPARATION OF 1-ARYL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTORS INHIBITORS | ESTEVE QUÍMICA S A (ES) | 2014-07-23 | — | — | EP | disclosed |
| US-20130184472-A1 | Process for the Preparation of 1-ARYL-PYRAZOL-3-ONE Intermediates Useful in the Synthesis of SIGMA Receptors Inhibitors | ESTEVE QUIMICA, S.A. (ES) | 2013-07-18 | — | — | US | disclosed |
| EP-2598469-A1 | PROCESS FOR THE PREPARATION OF 1-ARYL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTORS INHIBITORS | Esteve Química, S.A. (ES) | 2013-06-05 | — | — | EP | disclosed |
| EP-2418192-A1 | Intermediates for the preparation of 1-aryl-pyrazol-3-one compounds useful as sigma receptors inhibitors | Esteve Química, S.A. (ES) | 2012-02-15 | — | — | EP | disclosed |
| WO-2012013755-A1 | PROCESS FOR THE PREPARATION OF 1-ARYL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTORS INHIBITORS | Esteve Química, S.A. (ES) | 2012-02-02 | — | — | WO | disclosed |
| WO-2011005959-A1 | PROCESS FOR THE PREPARATION OF N-PROTECTED-DECYLAMINOETHANAL | PLUS CHEMICALS SA (CH) | 2011-01-13 | — | — | WO | disclosed |
| US-20110009596-A1 | PROCESS FOR THE PREPARATION OF N-PROTECTED-DECYLAMINOETHANAL | PLUS CHEMICALS SA (CH) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184472-A1 | Process for the Preparation of 1-ARYL-PYRAZOL-3-ONE Intermediates Useful in the Synthesis of SIGMA Receptors Inhibitors | SIGMAR1, OPRK1, OPRM1 | SLC6A2 180/4885SLC6A4 160/4885SLC6A3 252/4885 |
| US-20110009596-A1 | PROCESS FOR THE PREPARATION OF N-PROTECTED-DECYLAMINOETHANAL | PTMA, DNPEP, TET2 | SLC6A2 4442/4885SLC6A4 3750/4885SLC6A3 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.